for Prevention and treatment
“HAP2” is a 5-year project involving 10 partners from 6 countries, which aims to develop host-directed drugs and biomarkers to enhance the prevention and treatment of hospital-acquired pneumonia (HAP): an infectious disease of major concern for Europe, and develop precision medicine in infectious diseases.
HAP is defined as a respiratory tract infection that occurs 48 hours or more after hospital admission. It is the most frequent cause of hospital-acquired infections and the main cause of antibiotics consumption in European hospitals.
2020 > 2024